Bioidentical Hormones - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the bioidentical hormones market size is expected to grow from USD 4.05 billion in 2025 to USD 4.29 billion in 2026 and is forecast to reach USD 5.74 billion by 2031 at 5.99% CAGR over 2026-2031.

This report is Segmented by Hormone Type (Estrogens, Progesterone, and More), Product Type (Tablets and Capsules, Creams and Gels, and More), Route of Administration (Oral, Transdermal/Topical, Vaginal, and More), Application (Menopause Management, and More), Distribution Channel (Hospital, Retail, Online, and More), End User (Hospitals, and More), and Geography (North America, and More). Value (USD).

Global Bioidentical Hormones Market Trends and Insights

Rising Menopausal and Age-Related Hormone Deficiency Demand

The bioidentical hormones market is experiencing significant growth due to the increasing postmenopausal population. By 2025, over 1.1 billion women globally are expected to be postmenopausal, with more than 1.3 million women in the U.S. entering menopause annually. The financial impact of untreated symptoms is substantial, with annual productivity losses reaching USD 1.8 billion and combined medical and productivity costs at USD 26.6 billion in the U.S. Additionally, the market is recovering from a decline in hormone therapy usage caused by risk concerns from the WHI study, which reduced uptake from 27% to under 5% over two decades. Companies that can rapidly scale supply are well-positioned to capitalize on this rebound.

Demand for Personalized and Natural-Feeling Hormone Products

The market is shifting from standardized treatments to personalized approaches, focusing on individualized dosing, route selection, and symptom-specific management. Patients today are more informed and actively involved in treatment decisions, favoring options that mimic natural hormone patterns. However, approved products like BIJUVA, which introduced two-dose strengths in February 2026, are narrowing this gap. The market is moving toward regulated personalization, benefiting branded products that combine flexibility with the credibility of formal approval.

Guideline Skepticism Toward Compounded Bioidentical Hormone Therapy

Clinical skepticism continues to challenge the growth of the bioidentical hormones market, particularly regarding compounded bioidentical hormone therapy. The Endocrine Society and ACOG have highlighted the lack of evidence supporting the safety of compounded products over FDA-approved alternatives. ACOG also noted that compounded estradiol could test 26% below labeled content, while progesterone could test 31% above. This scrutiny is significant as the market has relied on compounding pharmacies to address dose and route needs unmet by approved products. In September 2025, the VA classified compounded bioidentical hormone therapy as investigational and unnecessary for menopause, male hypogonadism, and low libido, removing a key institutional prescribing pathway and potentially influencing other health systems. While demand remains strong, the market faces a stricter evidence and reimbursement environment.

Other drivers and restraints analyzed in the detailed report include:

1. Shift Toward Transdermal and Non-Oral Delivery for Better Outcomes
2. Telehealth-Enabled Hormone Care Pathways Expanding Access
3. Limited Reimbursement and Self-Pay Affordability Barriers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, estrogens accounted for 41.75% of the bioidentical hormones market, maintaining their position as a key revenue driver. Their dominance is due to their established role in treating vasomotor symptoms, genitourinary syndrome of menopause, and osteoporosis prevention. The 2025 Korean Society of Menopause guidelines highlighted the reduced risk of VTE and stroke with transdermal estradiol compared to oral routes, reinforcing estrogen products as the market's cornerstone.

Progesterone remains critical for women with an intact uterus, mitigating endometrial risks associated with unopposed estrogen therapy. Micronized progesterone and combination products continue to support prescription trends. DHEA, including FDA-approved vaginal prasterone, is a smaller but growing segment addressing genitourinary symptoms. Testosterone, with a projected CAGR of 6.30% through 2031, is the fastest-growing segment, driven by increased awareness of HSDD and androgen therapy, despite the absence of a female-specific approved product.

Patches and implants held a 41.6% market share in 2025 and are projected to grow at a 7.10% CAGR through 2031. Transdermal patches offer consistent estradiol delivery, bypass hepatic first-pass metabolism, and provide a safer option for women with thrombotic risks. Prescribers increasingly favor patches for balancing symptom control and cardiovascular risk.

Implants are gaining traction due to their long-acting hormone delivery and alignment with rising testosterone use in both genders. Subdermal pellets, offering sustained release and minimal daily intervention, have expanded the implant segment. Manufacturers with expertise in patch production or pellet systems are well-positioned to benefit from the shift away from oral products.

Geography Analysis

In 2025, North America accounted for 41.67% of the bioidentical hormones market, maintaining its leadership position. The U.S. drives this dominance due to regulatory changes, rising menopause treatment demand, robust telehealth infrastructure, and increased treatment awareness. Estrogen-based hormone therapy prescriptions among women aged 45 to 54 nearly doubled between 2023 and early 2026, reaching 5% of this demographic. Estrogen patch prescriptions also rose by 184% from 2018 to February 2026, reflecting a shift toward non-oral delivery methods. In Canada, Knight Therapeutics began commercializing IMVEXXY and BIJUVA in 2024 under its license from TherapeuticsMD, introducing institutional branding in a market previously dominated by compounded hormones.

Europe holds a mature yet evolving position in the bioidentical hormones market. Menopausal hormone therapy prevalence in Northern and Western Europe remains higher than the post-WHI U.S. levels, ranging from 4% to 10% in most EU markets. A joint statement by The British Menopause Society, the Royal College of Obstetricians and Gynaecologists, and the Society for Endocrinology supports no arbitrary age or duration limits on hormone therapy for symptomatic women. This provides a stable prescribing base, although compounded products face challenges related to evidence and reimbursement. The region combines strong clinical acceptance of therapy with stringent quality and evidence expectations.

Asia-Pacific is the fastest-growing region in the bioidentical hormones market, with a projected CAGR of 7.15% through 2031. Growth is driven by increased diagnoses, stronger guideline support, improved affordability of select products, and rising commercial investments. In China, menopausal hormone therapy prescriptions rose by 86.08% from 2019 to 2023, with prescription value increasing by 126.58%, despite a pandemic-related decline in 2020. The country also shows strong use of estrogen-progestogen compound preparations, supported by centralized procurement policies improving progesterone affordability.

1. Abbvie
2. AnazaoHealth
3. Besins Healthcare
4. BioTE Medical
5. BodyLogicMD
6. Compounding Pharmacy of America
7. Defy Medical
8. Empower Pharmacy
9. Fagron
10. JumpstartMD
11. Mayne Pharma
12. Neuva Aesthetics LLC.
13. Noven Pharmaceuticals Inc.
14. Papillon Medical Inc.
15. SottoPelle Therapy
16. The biostation
17. Theramex UK Ltd.
18. TherapeuticsMD
19. Wells Pharmacy Network
20. Women's International Pharmacy

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support